Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

PURPOSE: We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. METHODS: Twenty-four patients with CLL received lymphodepleting chemotherapy and anti-CD1...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Turtle, Cameron J., Hay, Kevin A., Hanafi, Laïla-Aïcha, Li, Daniel, Cherian, Sindhu, Chen, Xueyan, Wood, Brent, Lozanski, Arletta, Byrd, John C., Heimfeld, Shelly, Riddell, Stanley R., Maloney, David G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2017
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5590803/
https://ncbi.nlm.nih.gov/pubmed/28715249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.72.8519
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller